BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jones JE, Asato MR, Brown MG, Doss JL, Felton EA, Kearney JA, Talos D, Dacks PA, Whittemore V, Poduri A; NINDS/AES Benchmarks Stewards Committee. Epilepsy Benchmarks Area IV: Limit or Prevent Adverse Consequence of Seizures and Their Treatment Across the Life Span. Epilepsy Curr 2020;20:31S-9S. [PMID: 31973592 DOI: 10.1177/1535759719895277] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Heimfarth L, Passos FRS, Monteiro BS, Araújo AADS, Quintans Júnior LJ, Quintans JDSS. Serum glial fibrillary acidic protein is a body fluid biomarker: A valuable prognostic for neurological disease – A systematic review. International Immunopharmacology 2022;107:108624. [DOI: 10.1016/j.intimp.2022.108624] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Marsh ED, Whittemore V, Leenders M, Poduri A; American Epilepsy Society Epilepsy Research Benchmark Stewards Committee. The 2021 Epilepsy Research Benchmarks-Respecting Core Principles, Reflecting Evolving Community Priorities. Epilepsy Curr 2021;21:389-93. [PMID: 34924844 DOI: 10.1177/15357597211023712] [Reference Citation Analysis]
3 Elhady M, Youness ER, AbuShady MM, Nassar MS, Elaziz AA, Masoud MM, Foudaa FK, Elhamed WAA. Circulating glial fibrillary acidic protein and ubiquitin carboxy-terminal hydrolase-L1 as markers of neuronal damage in children with epileptic seizures. Childs Nerv Syst 2021;37:879-84. [PMID: 33044615 DOI: 10.1007/s00381-020-04920-z] [Reference Citation Analysis]